Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.7669
-0.0291-3.66%
Post-market: 0.79010.0232+3.03%19:42 EDT
Volume:1.78M
Turnover:1.40M
Market Cap:64.25M
PE:-0.26
High:0.8209
Open:0.7900
Low:0.7669
Close:0.7960
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
More
1D
5D
D
W
M
Q
Y
1m
5m
10m
15m
30m
1h
2h
Loading ...

Press Release: Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Dow Jones
·
13 Mar

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

GlobeNewswire
·
13 Mar

Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
11 Mar

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire
·
03 Mar

We're Not Very Worried About Sutro Biopharma's (NASDAQ:STRO) Cash Burn Rate

Simply Wall St.
·
22 Jan

Sutro Biopharma (STRO) Gets a Buy from Bank of America Securities

TIPRANKS
·
16 Jan

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
07 Jan

Sutro Biopharma and Boehringer Ingelheim Bioxcellence™ Collaboration: Established First-in-Class Cell-Free Capabilities at Commercial Scale

THOMSON REUTERS
·
07 Jan

Sutro Biopharma, Boehringer announce application of Sutro’s technology

TIPRANKS
·
07 Jan

Great week for Sutro Biopharma, Inc. (NASDAQ:STRO) institutional investors after losing 42% over the previous year

Simply Wall St.
·
07 Jan

Sutro Biopharma, Inc.'s (NASDAQ:STRO) latest 24% decline adds to one-year losses, institutional investors may consider drastic measures

Simply Wall St.
·
19 Dec 2024

Sutro Biopharma Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
11 Dec 2024

Truist Financial Reaffirms Their Buy Rating on Sutro Biopharma (STRO)

TIPRANKS
·
11 Dec 2024

Sutro Biopharma announces selected doses from REFRalphaME-O1

TIPRANKS
·
10 Dec 2024

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results From Dose-Optimization Portion of RefrΑMe-O1 Trial in Platinum Resistant Ovarian Cancer

THOMSON REUTERS
·
10 Dec 2024

Sutro Biopharma Inc - Luvelta Positioned for Accelerated Approval Application in Mid-2027

THOMSON REUTERS
·
10 Dec 2024

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."